by David Alcántara | Feb 7, 2024 | News
In a remarkable leap forward for vision science, the Limnopharma team has recently unveiled groundbreaking research in the fight against retinitis pigmentosa, a leading cause of inherited blindness. This achievement not only shines a light on new therapeutic avenues...
by David Alcántara | Jan 24, 2024 | News
Limnopharma, specialized in the development of new therapies for various retinal diseases, has been named one of the 100 best startups of 2023 by the Spanish Association of Science and Technology Parks (APTE). The company focuses on the development of new treatments...
by David Alcántara | Aug 9, 2023 | News
As a result of the collaboration with Inoviem company, the direct interaction between lim21 and one target protein has been established. The identification of this target protein is in line with previous findings and corroborates a pathway involving activation of...
by David Alcántara | Jul 26, 2023 | News
Dr. Francisco Javier Díaz Corrales, co-founder of Limnopharma and renowned scientist at the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), has been awarded a prestigious award for his leadership and dedication in gene therapy research for...
by David Alcántara | Dec 12, 2022 | News
In 2022, Limnopharma engaged in numerous investment events and biotechnology expos. The initial half of the year saw us participating virtually, but from May onwards, we transitioned to in-person attendance. Our involvement included the virtual Bioeurope Spring,...
by David Alcántara | Nov 17, 2022 | News
Limnopharma’s team in collaboration with Prof. Alberto Zafra from the University of Granada has just carried out biodistribution experiments of LIM21 administered in eye drops in pigs. The animals were handled by expert veterinarians at IAVANTE, located in the Health...
